Blog
Published July 6, 2021
Executive Summary
The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance
Since 2017, on average, a significant price discount of 44-61% was required for products to achieve a positive listing on the NRDL
Based on average 2018 sales data, products included on the 2017 NRDL were able to achieve an increase in sales revenue (188%) despite the steep average…
Read Now
Blog
Published June 2, 2021
Executive Summary
The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland
The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years
The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date
Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…
Read Now
Blog
Published May 25, 2021
Executive Summary
Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing success
Dynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access outcomes
Trinity’s Take: In this article, Trinity uses select combination case studies to highlight the key elements to consider when thinking through price / access strategy for a novel combination
Evaluation of the Novel Combinations Landscape
The pursuit of a successful…
Read Now
Webinars
Available On Demand
Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.
But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
What are the ‘nuts and bolts’ of designing and conducting such studies?
How do you distill down to the key value messages from a complex data set to be most impactful to clinical…
Watch Now
Webinars
Available On Demand
A diverse workforce signals competent management for investors and is a better reflection of your customers.” – VP, Commercial Operations
TGaS Advisors, a division of Trinity Life Sciences, partnered with EMD Serono to develop Company and Pipeline Development Scorecards from a benchmark study of life sciences compared to ex-industry best practice research, including surveys/interviews with 23 unique life science companies in the TGaS Client Network. Join us to hear findings from the study.
Key Webinar Topics
Why and how does…
Watch Now
Blog
Published February 19, 2021
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam…
Read Now
Webinars
Available On Demand
Are you a leader in a pre-commercial company evaluating your contract administration needs?
Are you a leader in a commercial company struggling with manual contract administration processes?
If either scenario sounds familiar, watch our latest webinar, Enabling Contract Administration Capabilities. TGaS Advisors, a division of Trinity Life Sciences, has designed this webinar specifically for Market Access and Contracting leaders in pre-commercial and emerging life science companies. During the webinar, we discuss industry best practices and approaches for building and optimizing…
Watch Now
Blog
Published November 3, 2020
Executive Summary
Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially
To date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approval
There have been multiple challenges involved when trying to successfully commercialize the products, but the landscape looks…
Read Now
Blog
Published November 3, 2020
Written by Tom Rutkowski and Patrick Buck…
Read Now
Webinars
Available On Demand
How has COVID-19 impacted launch performance and timing?
Pharmaceutical leaders are facing some of the toughest challenges of their careers when it comes to launching in the midst of COVID-19. With so much at stake and so much uncertainty, companies are looking for fact-based insights to power their decision-making.
Trinity has done an in-depth evaluation of the impact of COVID-19 on launch performance and timing. We have compared forecasted/expected revenue to actual revenue for products that launched within six months…
Watch Now
